These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 10811495)
1. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours. Imam H; Eriksson B; Oberg K Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495 [TBL] [Abstract][Full Text] [Related]
2. Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors. Granberg D; Wilander E; Oberg K; Skogseid B Int J Cancer; 1999 Oct; 84(5):484-88. PubMed ID: 10502723 [TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 variants in osteosarcoma. Kuryu M; Ozaki T; Nishida K; Shibahara M; Kawai A; Inoue H J Cancer Res Clin Oncol; 1999 Nov; 125(11):646-52. PubMed ID: 10541973 [TBL] [Abstract][Full Text] [Related]
4. CD44 loss in gastric stromal tumors as a prognostic marker. Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305 [TBL] [Abstract][Full Text] [Related]
5. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Li Z; Chen K; Jiang P; Zhang X; Li X; Li Z Diagn Pathol; 2014 Apr; 9():79. PubMed ID: 24708709 [TBL] [Abstract][Full Text] [Related]
6. [Expression of CD44 and isoforms v4, v5, v6, v7, v10--new prognostic parameters in ductal pancreatic carcinoma?]. Böttger T; Maschek H; Gottwald W; Lobo M; Brenner W; Junginger T Chirurg; 1998 Oct; 69(10):1089-92. PubMed ID: 9833191 [TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672 [TBL] [Abstract][Full Text] [Related]
8. Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours. Terris B; Fléjou JF; Dubois S; Ruszniewski P; Scoazec JY; Belghiti J; Potet F; Bernades P; Mignon M; Hénin D Clin Mol Pathol; 1996 Aug; 49(4):M203-8. PubMed ID: 16696075 [TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625 [TBL] [Abstract][Full Text] [Related]
10. CD44 expression in soft tissue sarcomas. Kahara N; Ozaki T; Doi T; Nishida K; Kawai A; Shibahara M; Inoue H Virchows Arch; 2000 Jun; 436(6):574-8. PubMed ID: 10917171 [TBL] [Abstract][Full Text] [Related]
11. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Bànkfalvi A; Terpe HJ; Breukelmann D; Bier B; Rempe D; Pschadka G; Krech R; Böcker W Histopathology; 1998 Aug; 33(2):107-16. PubMed ID: 9762542 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890 [TBL] [Abstract][Full Text] [Related]
13. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Tran TA; Kallakury BV; Sheehan CE; Ross JS Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer. Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044 [TBL] [Abstract][Full Text] [Related]